April 3 (Reuters) - Lenz Therapeutics said on Wednesday its experimental drugs to treat loss of near vision met the main goal of a late-stage study. (Reporting by Sneha S K in Bengaluru; Editing by Shilpi Majumdar)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.72 USD | -1.19% | -4.32% | 0.00% |
Apr. 15 | Leerink Partners Starts LENZ Therapeutics With Outperform Rating, $32 Price Target | MT |
Apr. 15 | William Blair Starts LENZ Therapeutics With Outperform Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 406M | |
+5.33% | 111B | |
+12.11% | 105B | |
-12.56% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.86% | 16.96B | |
+5.10% | 13.7B | |
+37.57% | 12.45B |
- Stock Market
- Equities
- LENZ Stock
- News LENZ Therapeutics, Inc.
- Lenz Therapeutics' eye disease drugs meet main goal of late-stage study